National Brain Tumor Society - Public Policy and Advocacy Update
Vol. 4 No. 7

  • Congress’ Summer Recess Begins August 3rd
  • Conquer Childhood Cancer STAR Act Introduced!
  • Oral Chemotherapy Parity Legislation
  • 21st Century Cures Act – On to the Senate

Congress’ Summer Recess Begins August 3rd
Starting August 3rd, Members of Congress head back home to their local districts to hear directly from you, their constituent, about the issues that are most important to you. August recess lasts through September 7th and is the optimal time for you to engage with your Members of Congress and their offices. Check out our August recess page to learn how easy it is to schedule in-district meetings and to download the materials you need to be a successful advocate.

Conquer Childhood Cancer STAR Act Introduced!
Thanks to your support for National Brain Tumor Society, we are excited to announce an important outcome. On a bipartisan basis, the Conquer Childhood Cancer Survivorship, Treatment, Access, Research (STAR) Act was introduced in both chambers of Congress this week by Sens. Reed (RI) and Capito (WV) and Reps. McCaul (TX) and Van Hollen (MD). National Brain Tumor Society, as a member of the Alliance for Childhood Cancer has worked to ensure that the robust legislation strengthens pediatric brain tumor research, improves expanded access to investigational new treatments and provides new funding to develop models of care for pediatric brain tumor survivors. In addition, the legislation would guarantee that pediatric cancer expertise will be included in the National Cancer Institute's top advisory group. The introduction of this bill is a major milestone in our efforts to improve research, the development of new treatments and care for pediatric brain tumor patients today and all those who may be diagnosed tomorrow. Already National Brain Tumor Society’s State Lead Advocates and Advocacy Ambassadors have played a key role in recruiting early support for the legislation. The next step is for our community to get engaged and advocate. Keep an eye out for an explanatory issue brief and action alert advocacy opportunities.

Oral Chemotherapy Parity Legislation
We continue to work alongside our Patients Equal Access Coalition (PEAC) partners to engage Members of Congress and activate you, our advocate community, as we ask Members to co-sponsor the Cancer Drug Coverage Parity Act of 2015 in both the House and Senate. These bills are in the early phase of the legislative process so stay tuned for action alerts on this issue as we move forward.

21st Century Cures Act – On to the Senate
The passage of the 21st Century Cures Act (H.R. 6) in the U.S. House of Representatives has the nation talking about the potential for advancing many aspects of America’s biomedical research infrastructure into the 21st Century. For the brain tumor community, the 21st Century Cures Act is a significant step forward for policies that will support our efforts to deliver new, effective treatments, and ultimately a cure, for brain tumors. Now, as the Senate creates a companion bill to H.R. 6, we will work closely with Congress, advocacy partners and the brain tumor community to ensure that critical provisions for brain tumor patients continue to be included. Click here to review our analysis of the legislation and its potential impact on brain tumor patients.  

Thank you again for all your support and advocacy!

David F. Arons, JD

Chief Public Policy
and Advocacy Officer

Lainey Titus Samant

Associate Director

Tyler Gately

Manager of Advocacy
and Volunteer Leadership

National Brain Tumor Society is fiercely committed to finding better treatments, and ultimately a cure, for people living with a brain tumor today and those who will be diagnosed tomorrow. This means effecting change in the system at all levels. It's time to build on progress and transform tomorrow today.

Was this e-mail forwarded to you? Subscribe today.

55 Chapel Street, Suite 200, Newton, MA 02458

617.924.9997 | Contact Us | | Donate

© National Brain Tumor Society - All Rights Reserved.